^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MET exon 14 deletion

    i
    Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
    Entrez ID:
    4233
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over1year
    Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors. (PubMed, Target Oncol)
    The safety profile of single-agent glesatinib was acceptable. SDD 750 mg twice daily was selected as the preferred glesatinib formulation and dose based on clinical activity, safety, and PK data. Observations from this study led to initiation of a phase II study of glesatinib in patients with NSCLC stratified by type of MET alteration (NCT02544633).
    P1 data • Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • AXL (AXL Receptor Tyrosine Kinase)
    |
    MET amplification • MET exon 14 mutation • MET overexpression • AXL overexpression • MET exon 14 deletion
    |
    glesatinib (MGCD265)
    almost2years
    Discrepancy in MET Exon 14 Skipping Mutation Measurement Between ArcherMET and Oncomine Dx Target Test System (IASLC-WCLC 2022)
    One of the selective oral MET inhibitors, tepotinib, is only used in Japan when METex14skipping is detected by ArcherMET, a next generation sequencer... The discrepancies observed between these systems may be owing to low allele frequencies. More analysis for these are warranted.
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET exon 14 mutation • MET exon 14 deletion
    |
    Oncomine™ Dx Target Test • ArcherMET
    |
    Tepmetko (tepotinib)
    almost4years
    [VIRTUAL] Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmp/Ex14∆). (ASCO 2020)
    P1a | "Sym015 was well-tolerated at the RP2D with a response rate similar to MET TKI in MET-treatment naïve METAmp/Ex14Δ NSCLC and seems to delay disease progression in MET TKI pretreated NSCLC pts. Combination with MET TKI to delay or prevent resistance should be further explored. Research Funding: Symphogen A/S"
    Clinical
    |
    MET amplification • MET exon 14 mutation • MET exon 14 deletion
    |
    Guardant360® CDx
    |
    S95027
    over4years
    Phase 1 Study of TPX-0022, a MET/CSF1R/SRC Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in MET (clinicaltrials.gov)
    P1, N=120, Recruiting, Turning Point Therapeutics, Inc. | Initiation date: Dec 2019 --> Aug 2019
    Clinical • Trial initiation date
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation • MET exon 14 deletion
    |
    elzovantinib (TPX-0022)